Abstract 70P
Background
The efficacy and safety of the three-drug combination of eribulin (E), trastuzumab (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) as first-line treatment was reported. The overall response rate (complete response [CR] + partial response [PR]) was 80.0% (95% confidence interval [CI], 59.3–93.2%), and the clinical benefit rate (CR + PR + stable disease ≥24 weeks; CBR) was 84.0% (95% CI, 63.9–95.5%). Median time to treatment failure with E was 9.1 months (95% CI, 4.3–13.9 months), and median progression-free survival was 23.1 months (95% CI, 14.4–31.8 months). The most common treatment-emergent adverse events (TEAEs) were alopecia (92.0%), fatigue (68.0%), and sensory peripheral neuropathy (60.0%). Grade 3/4 TEAEs occurred in 11 patients (44.0%). The only grade 4 TEAE was neutrophil count decreased (16.0%). Neither grade 4 peripheral neuropathy nor febrile neutropenia occurred (Inoue K et al Investigational New Drugs 2019; 180:135–46). We report the overall survival results and the efficacy of post-ETP treatments at 5.5 years after the last enrollment.
Methods
E 1.4 mg/m2 (days 1 and 8), T 8 mg/kg over 90 min and 6 mg/kg over 30 min, and P 840 mg/body over 60 min and 420 mg/body over 30 min were administered intravenously in 21-day cycles.
Results
From April 2016 to November 2017, 25 women received ETP therapy and 12 of the 25 survived with a median OS of 78.4 months, 95% CI 26.4-NA months. Subset analysis by log-rank test showed a significant difference (P=0.0114) and hazard ratio; 3.063 95% CI 1.002-9.361 in hemoglobulin (≥12 vs. ≤12 mg/dl), but not in estrogen receptor status and neutrophil/lymphocyte ratio (≥2 vs. <2). T-emtansine, capecitabine + TP, T-deruxtecan, and epirubicin + cyclophosphamide were administered after ETP with CBR of 72.2% (13/18 patients), 80.0% (4/5 patients), 66.7% (2/3 patients) and 33.3% (1/3 patients), respectively.
Conclusions
ETP therapy showed acceptable efficacy and overall survival as first-line therapy for patients with HER2-positive Japanese MBC.
Clinical trial identification
UMIN000021585.
Editorial acknowledgement
Legal entity responsible for the study
Saitama breast cancer clinical study group.
Funding
Has not received any funding.
Disclosure
K. Inoue: Financial Interests, Institutional, Funding: AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa-Kirin, MSD, Novartis, Pfizer, Taiho, Ono, Astellas, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract